Abstract

In addition to its bronchodilating activity, the antiasthmatic drug theophylline also reduces microvascular permeability and increases mucociliary clearance, diaphragmatic contractility, and circulating catecholamine levels. Both experimental and clinical data now suggest that at therapeutic serum levels, theophylline is also of value during the delayed asthmatic reaction by inhibiting airway inflammation and the associated bronchial responsiveness. In vitro, high theophylline concentrations inhibit histamine release from mast cells and basophils. This drug also suppresses polymorphonuclear leukocyte activation and stabilizes a variety of inflammatory cells at therapeutically relevant concentrations.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.